"Ryan Sperry, VP of integrated client solutions, Basis Technologies: The Trump administration and those close to it have made it clear they’re not fans of how prevalent pharma marketing is in the U.S. Some of the opinions from those like RFK Jr. even suggest getting rid of pharmaceutical advertising altogether, though that would clash with First Amendment protections. I expect the industry will see tighter regulations around how patient data is used in advertising, a trend already occurring with legislation like Washington’s My Health My Data Act, which other states are beginning to adopt."
Read more in MedAdNews.
